Sat, Nov 1, 2014, 8:36 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • greens150 greens150 Jun 5, 2013 8:07 AM Flag

    Excellent Guidance for '13 and Expectations for 2014

    Always under-promise and over-deliver. Their reps must have been hitting the pavement really good and have been seeing great responses from Doctors to give that type of guidance. If they say $150mm, I'm thinking $175-$2000mm.

    As for 2014, remember that prescriptions are like subscriptions, recurring revenue. $150mm for 6 doesn't mean $300mm for 12, it means more like $500mm to $750mm for 12 months as there will be patients that get prescriptions in Jun-Aug that continue into 2014, as well as many that start in Sept-Dec that take Belviq at a minimum into March and some throughout '14; plus all the NEW prescriptions that are written in '14 from a combination of Eisai's efforts as well as compounding word of mouth from the patients that have taken it in the 1st 6 months.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 150, I too agree. 150M is a very modest projection once you read SpencSA 10,000 scripts to start in June and going on from there; that's extremely modest! But why I suggest 0.5B in the first year is because 150M x 2 = 300M, doesn't account for exponential growth over that same period which after 12 months should be closer to $500M full year guidance. Even if we accept a flat line via Eisai, that's 300M/yr and this is news the Street is going to have to consume. I maintain 0.5B is a fair estimate based on Eisai's number calculating in exponential growth.=SV

    • I have to agree with you. I also believe that base upon ARNA and EISAI's history they are not out to pump a medication or their stock and are being conservative. I really like that. I hate companies that pump and dump without delivering, like DNDN and VVUS.

      GLTA Longs

      Sentiment: Hold

4.36-0.09(-2.02%)Oct 31 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.